MA37471A1 - Formulation lyophilise et aqueuse d’anticorps anti-cd40 - Google Patents

Formulation lyophilise et aqueuse d’anticorps anti-cd40

Info

Publication number
MA37471A1
MA37471A1 MA37471A MA37471A MA37471A1 MA 37471 A1 MA37471 A1 MA 37471A1 MA 37471 A MA37471 A MA 37471A MA 37471 A MA37471 A MA 37471A MA 37471 A1 MA37471 A1 MA 37471A1
Authority
MA
Morocco
Prior art keywords
lyophilizate
antibodies
antibody
aqueous
lyophilized
Prior art date
Application number
MA37471A
Other languages
English (en)
Inventor
Claudia Mueller
Matthias Willmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48626495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37471(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA37471A1 publication Critical patent/MA37471A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Cette invention concerne des anticorps anti-cd40 formulés sous la forme d'un lyophilisat ou d'une formulation liquide. Les lyophilisats peuvent être reconstitués pour obtenir une solution ayant une concentration élevée en principe actif d'anticorps pour être administrée à un patient sans niveaux élevés d'agrégation d'anticorps. Le lyophilisat peut être reconstitué à l'aide d'un reconstituant aqueux pour obtenir une composition aqueuse ayant une concentration d'anticorps d'au moins 50 mg/ml. Le lyophilisat ou la composition pharmaceutique aqueuse peut comprendre un ou plusieurs autres composés parmi un sucre, un agent de tamponnage, un tensioactif, et/ou un acide aminé libre.
MA37471A 2012-05-04 2013-05-02 Formulation lyophilise et aqueuse d’anticorps anti-cd40 MA37471A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642644P 2012-05-04 2012-05-04
PCT/IB2013/053490 WO2013164789A2 (fr) 2012-05-04 2013-05-02 Formulation d'anticorps

Publications (1)

Publication Number Publication Date
MA37471A1 true MA37471A1 (fr) 2016-07-29

Family

ID=48626495

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37471A MA37471A1 (fr) 2012-05-04 2013-05-02 Formulation lyophilise et aqueuse d’anticorps anti-cd40

Country Status (29)

Country Link
US (5) US20140004131A1 (fr)
EP (2) EP3693016A1 (fr)
JP (1) JP6007316B2 (fr)
KR (1) KR101782203B1 (fr)
CN (1) CN104302320B (fr)
AR (1) AR095451A1 (fr)
AU (2) AU2013255457A1 (fr)
BR (1) BR112014027116B1 (fr)
CA (1) CA2870338C (fr)
CL (1) CL2014002823A1 (fr)
CO (1) CO7111300A2 (fr)
DK (1) DK2844286T3 (fr)
EA (1) EA031436B1 (fr)
ES (1) ES2788515T3 (fr)
HK (1) HK1202050A1 (fr)
HU (1) HUE048895T2 (fr)
IL (1) IL235216A0 (fr)
MA (1) MA37471A1 (fr)
MX (1) MX357845B (fr)
PE (1) PE20142407A1 (fr)
PH (1) PH12014502460A1 (fr)
PL (1) PL2844286T3 (fr)
PT (1) PT2844286T (fr)
SG (1) SG11201406335PA (fr)
SI (1) SI2844286T1 (fr)
TN (1) TN2014000431A1 (fr)
TW (1) TW201347791A (fr)
WO (1) WO2013164789A2 (fr)
ZA (1) ZA201407192B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123489A2 (fr) 2010-03-31 2011-10-06 Boehringer Ingelheim International Gmbh Anticorps anti-cd40
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
CA2938933A1 (fr) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anticorps anti-laminine4 specifiques contre lg4 -5
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
US20180133375A1 (en) * 2014-10-30 2018-05-17 Chugai Seiyaku Kabushiki Kaisha Pre-Filled Syringe Formulation With Needle, Which Is Equipped With Syringe Cap
KR102656470B1 (ko) 2014-12-10 2024-04-09 리전츠 오브 더 유니버스티 오브 미네소타 질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기
PL3344655T3 (pl) * 2015-09-01 2024-02-19 Boehringer Ingelheim International Gmbh Zastosowanie przeciwciał anty-cd40 w leczeniu toczniowego zapalenia nerek
WO2017046776A2 (fr) * 2015-09-16 2017-03-23 Prothena Biosciences Limited Utilisation d'anticorps anti-mcam pour le traitement ou la prophylaxie de l'artérite à cellules géantes, la pseudo-polyarthrite rhizomélique ou l'artérite de takayasu
TWI826351B (zh) * 2016-05-31 2023-12-21 大陸商鴻運華寧（杭州）生物醫藥有限公司 Ｒ抗體,其藥物組合物及其應用
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
TW202228779A (zh) 2017-03-01 2022-08-01 英商梅迪繆思有限公司 抗rsv單株抗體配製物
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
CA3076872A1 (fr) * 2017-11-03 2019-05-09 Novartis Ag Anticorps anti-cd40 destines a etre utilises dans le traitement du syndrome de sjogren
CA3103629A1 (fr) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Augmentation de l'activite immunitaire par modulation de facteurs de signalisation post-cellulaires
SG11202103907PA (en) * 2018-10-18 2021-05-28 Merck Sharp & Dohme Formulations of anti-rsv antibodies and methods of use thereof
JP7369470B2 (ja) 2018-11-29 2023-10-26 エプシタウ リミテッド 混合相磁石リングを備える軽量の非対称磁石アレイ
AU2019407063A1 (en) 2018-12-18 2021-05-27 Novartis Ag Protein solution formulation containing high concentration of an anti-VEGF antibody
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
EP3962493A2 (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
US20230348609A1 (en) * 2020-08-21 2023-11-02 Wuxi Biologics (Shanghai) Co. Ltd. Cd40 agonistic antibody and method of use
CN114762727A (zh) * 2021-01-15 2022-07-19 海正生物制药有限公司 一种稳定的帕妥珠单抗的药物组合物
CA3214085A1 (fr) 2021-03-31 2022-10-06 Darby Rye Schmidt Polypeptides de thanotransmission et leur utilisation dans le traitement du cancer
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
WO2023044048A1 (fr) 2021-09-17 2023-03-23 Novartis Ag Méthodes de prévention du rejet de greffe dans une xénogreffe
WO2023169986A1 (fr) * 2022-03-07 2023-09-14 Mabxience Research, S.L. Formulations stables pour anticorps
WO2024077191A1 (fr) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0401384B1 (fr) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
CA2226575C (fr) 1995-07-27 2011-10-18 Genentech, Inc. Formulation de proteine lyophilisee isotonique et stable
TR199903141T2 (xx) 1997-06-20 2000-09-21 Biogen, Inc. Terap�tik protein engelleyici sendrom i�in CD154 blokaj tedavisi.
PT1224940E (pt) 1997-09-23 2005-01-31 Rentschler Biotech Gmbh Formulacoes liquidas de intrferao beta
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
WO2004071439A2 (fr) 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Preparation d'immunoglobuline et son procede de production
EP1694360B1 (fr) 2003-11-04 2010-08-04 Novartis Vaccines and Diagnostics, Inc. Utilisation d'anticorps antagonistes anti-cd40 pour le traitement de maladies autoimmunes et inflammatoires et le rejet d'organes transplantes
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
CA2560742A1 (fr) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Agents de couplage recepteurs et leurs applications therapeutiques
WO2006073443A2 (fr) 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Anticorps monoclonaux anti-cd40 antagonistes et leurs methodes d'utilisation
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20080057070A1 (en) 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
JP5421590B2 (ja) 2005-05-18 2014-02-19 ノバルティス アーゲー 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法
CN101351478A (zh) 2005-11-01 2009-01-21 诺华有限公司 抗cd40抗体的应用
CA2638811A1 (fr) * 2006-02-03 2007-08-16 Medimmune, Llc Formulations de proteines
US7846724B2 (en) * 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
EA018301B1 (ru) * 2006-04-21 2013-07-30 Новартис Аг Фармацевтические композиции, содержащие антагонистическое моноклональное антитело к cd40, и их применение
AU2008260498B2 (en) 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
BRPI0820407A2 (pt) * 2007-11-09 2015-05-26 Novartis Ag Uso de anticorpos anti-cd40
CA2722466A1 (fr) 2008-04-29 2009-11-05 Tariq Ghayur Immunoglobulines a double domaine variable et utilisations
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
PE20120341A1 (es) * 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
IN2012DN02737A (fr) 2009-09-01 2015-09-11 Abbott Lab
US20130136733A1 (en) * 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
JP2013531679A (ja) * 2010-07-02 2013-08-08 メディミューン，エルエルシー 抗体製剤
KR101867279B1 (ko) * 2010-10-06 2018-06-15 리제너론 파아마슈티컬스, 인크. 항―인터류킨―４ 수용체（ｉｌ－４ｒ） 항체를 함유하는 안정화된 제형
KR20180129991A (ko) * 2010-11-05 2018-12-05 노파르티스 아게 Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
EP2648750B1 (fr) * 2010-12-10 2017-01-25 Novartis AG Formulation d'anticorps
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation

Also Published As

Publication number Publication date
WO2013164789A3 (fr) 2014-02-13
MX2014013434A (es) 2015-05-11
CA2870338C (fr) 2020-08-11
CN104302320B (zh) 2016-12-21
CA2870338A1 (fr) 2013-11-07
ES2788515T3 (es) 2020-10-21
AU2013255457A8 (en) 2014-11-06
HK1202050A1 (en) 2015-09-18
US20180169246A1 (en) 2018-06-21
US11612659B2 (en) 2023-03-28
EP3693016A1 (fr) 2020-08-12
CL2014002823A1 (es) 2014-12-19
EP2844286B1 (fr) 2020-02-19
CO7111300A2 (es) 2014-11-10
TN2014000431A1 (en) 2016-03-30
JP6007316B2 (ja) 2016-10-12
TW201347791A (zh) 2013-12-01
SI2844286T1 (sl) 2020-07-31
PH12014502460A1 (en) 2014-12-22
CN104302320A (zh) 2015-01-21
PL2844286T3 (pl) 2020-07-27
PT2844286T (pt) 2020-05-25
AU2013255457A1 (en) 2014-10-23
EP2844286A2 (fr) 2015-03-11
WO2013164789A2 (fr) 2013-11-07
BR112014027116A2 (pt) 2017-08-08
SG11201406335PA (en) 2014-11-27
US10588976B2 (en) 2020-03-17
US20140004131A1 (en) 2014-01-02
MX357845B (es) 2018-07-26
BR112014027116B1 (pt) 2022-02-15
PE20142407A1 (es) 2015-01-16
US20200397903A1 (en) 2020-12-24
ZA201407192B (en) 2015-12-23
KR20150008892A (ko) 2015-01-23
US20150086559A1 (en) 2015-03-26
US10111958B2 (en) 2018-10-30
EA031436B1 (ru) 2019-01-31
IL235216A0 (en) 2014-12-31
AR095451A1 (es) 2015-10-21
HUE048895T2 (hu) 2020-08-28
EA201492021A1 (ru) 2015-02-27
JP2015522524A (ja) 2015-08-06
KR101782203B1 (ko) 2017-09-26
AU2016204371B2 (en) 2017-10-26
DK2844286T3 (da) 2020-05-18
US20190151450A1 (en) 2019-05-23
AU2016204371A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
MA37471A1 (fr) Formulation lyophilise et aqueuse d’anticorps anti-cd40
MA37616A1 (fr) Formulation liquide d'anticorps anti-baffr pour une utilisation dans le traitement de maladies auto-immunes et du neoplasme cellulaire.
JP6861682B2 (ja) コエンザイムＱ１０（ＣｏＱ１０）の静脈内投与用製剤およびその使用方法
PH12017500844B1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
MA35136B1 (fr) Formulation pour un anticorps anti-a4b7
RS54769B1 (sr) Visoko koncentrovane farmaceutske formulacije koje sadrže anti-cd20 antitelo
WO2007027941A3 (fr) Compositions et methode de preparation de medicaments a faible solubilite dans l'eau presentant une stabilite accrue
MA38576A1 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
BR112014019667A2 (pt) formulação de anticorpo abeta
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
PE20131324A1 (es) Formulacion subcutanea de anticuerpo anti-her2
PE20090064A1 (es) Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
US20170216223A1 (en) Methods of treatment of solid tumors using coenzyme q10
EA200800360A1 (ru) Формуляции с высоким содержанием лекарства и дозированные формы
US20220202741A1 (en) Methods of treatment of temozolomide-resistant glioma using coenzyme q10
MA34225B1 (fr) Préparation stable de mia/cd-rap
MA43686A (fr) Formulation liquide stable de gonadotrophines
MA33356B1 (fr) Compose anticancereux et composition pharmaceutique le contenant
MX2021007393A (es) Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf.
MA31913B1 (fr) Compositions pharmaceutiques contenant des antagonistes de la bradykinine et de l'acide hyaluronique, et leurs utilisations
JP2017524036A (ja) 薬物及び他の物質の送達のための経口組成物
AR127813A1 (es) FORMULACIONES FARMACEUTICAS QUE COMRENDEN Fab-PEG
AR102572A1 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf
WO2021121444A3 (fr) Formulation stable et de haute concentration de l'anticorps nimotuzumab
CR20200240A (es) Formulación farmacéutica estable de una proteína de fusión